Supreme Court re­jects No­var­tis' re­quest for stay in Gilenya patent bat­tle

Af­ter tak­ing its Gilenya patent bat­tle all the way to the Supreme Court last month, No­var­tis suf­fered yet an­oth­er loss on Thurs­day — but it isn’t done fight­ing yet.

The Supreme Court has de­nied No­var­tis’ re­quest to stay a low­er court’s man­date in­val­i­dat­ing a key Gilenya patent. The Swiss phar­ma gi­ant says it stands to lose more than a quar­ter bil­lion dol­lars in sales this year if gener­ics for the block­buster mul­ti­ple scle­ro­sis treat­ment are al­lowed to mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.